Biotechnology | COVID-19 | FDA | NIH | Therapeutics
Medigen Vaccines obtained TFDA phase 2 IND approval for COVID19 vaccine
On Dec. 30, 2020, Medigen Vaccine Biologics announced that it had obtained TFDA Phase 2 IND approval of…
Mateon global study for OT-101/ TGF-inhibitor against COVID-19 treated its first patient
On Dec. 30, 2020, Mateon Therapeutics announced that it had enrolled and treated its first sentinel Part 1…
Biotechnology | Disease | FDA | Therapeutics
FDA approved first generic of drug used to treat severe hypoglycemia
On Dec. 28, 2020, the U.S. Food and Drug Administration approved the first generic of glucagon for injection…
The Serum Institute of India launched India’s first indigenously developed pneumococcal vaccine
On Dec. 28, 2020, Serum Institute of India announced the launch of India’s first indigenously developed pneumococcal vaccine…
AIM ImmunoTech announced availability of ME/CFS clinical trial of drug Ampligen for enrollment to COVID-19 ‘Long Haulers’
On Dec. 24, 2020, AIM ImmunoTech announced that the post-COVID-19 ‘Long Hauler’ portion of the active AMP-511 Expanded…
Cocrystal Pharma selected lead compound for further development against Coronaviruses
On Dec. 22, 2020, Cocrystal Pharma announced the selection of CDI-45205 as the lead compound for further development…
Biotechnology | COVID-19 | FDA | Therapeutics
Sorrento announced it had submitted an EUA application to the FDA for COVI-STIX rapid test for detection of SARS-CoV-2 antigen
On Dec. 22, 2020, Sorrento Therapeutics announced that an Emergency Use Authorization (EUA) Application had been submitted to…
RedHill’s phase 2/3 COVID-19 study of opaganib passed second DSMB with unanimous recommendation
On Dec. 22, 2020, RedHill Biopharma announced that the global Phase 2/3 study with orally-administered opaganib (Yeliva, ABC294640)1…
European Commission approved Aimmune’s PALFORZIA as first-ever treatment for peanut allergy in the EU
On Dec. 21, 2020, Aimmune Therapeutics announced that the European Commission (EC) had approved PALFORZIA [defatted powder of…
Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATY
On Dec. 19, 2020, Pfizer and BioNTech announced they supplying an additional 100 million doses of COMIRNATY the…
Biotechnology | Diagnostics | Disease | FDA | Oncology | Radiology | Therapeutics
FDA approved first adjuvant therapy for most common type of lung cancer
On Dec. 18, 2020, the the U.S. Food and Drug Administration (FDA) approved AstraZeneca’s Tagrisso (osimertinib) as the…
National Research Council of Canada supported development of 4 COVID-19 therapeutic candidates
On Dec. 18, 2020, the National Research Council of Canada (NRC) announced it was providing advisory services and…
Lilly began pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19 in New Mexico
On Dec. 18, 2020, Eli Lilly announced plans to begin a new pragmatic study of bamlanivimab (LY-CoV555) in…
RedHill’s phase 2/3 COVID-19 candidate opaganib reduced ARDS-related blood clotting in preclinical model
On Dec. 15, 2020, a months long study to determine the number of Houstonians carrying COVID-19 antibodies revealed…
Aurinia and Lonza announced exclusive agreement for dedicated Voclosporin manufacturing capacity
On Dec. 15, 2020, Aurinia Pharmaceuticals announced the funding and initiation of an open-label exploratory trial evaluating the…
INOVIO to develop DNA-encoded monoclonal antibody (dMAb) candidates to treat COVID-19
On Dec. 15, 2020, Inovio Pharma announced the company and a team of scientists from The Wistar Institute,…
Anixa Biosciences Covid-19 therapy demonstrated comparable potency to remdesivir in pre-clinical testing
On Dec. 14, 2020, Anixa Biosciences announced that it and partner OntoChem GmbH had verified that one of…
Biotechnology | CRISPR | FDA | Therapeutics
CIRM-funded project targeting sickle cell disease received green light for clinical trial
On Dec.14, 2020, the US Food and Drug Administration (FDA) announced they had granted Investigational New Drug (IND)…
Incyte announced results of phase 3 study of Ruxolitinib (Jakafi) as treatment for patients with COVID-19 associated cytokine storm
On Dec. 14, 2020, Incyte announced that the Phase 3 RUXCOVID study evaluating the safety and efficacy of…
AI test ruled out a COVID-19 diagnosis within one hour in Emergency Departments
On Dev. 11, 2020, the University of Oxford reported that an Artificial Intelligence test had been shown to…
COVID-19 | FDA | Therapeutics
Data from ACTT-2 trial of Baricitinib in hospitalized COVID-19 patients supportive of the EUA published in NEJM
On Dec. 11, 2020, Eli Lilly and Incyte announced The New England Journal of Medicine had published the…
Matinas BioPharma announced collaboration with NIAID to evaluate Gilead’s antiviral remdesivir
On Dec. 7, 2020, Matinas BioPharma announced that they planned to collaborate with the National Institute of Allergy…
High-dose influenza vaccine showed no additional benefit for heart disease patients
On Dec. 4, 2020, it was reported in JAMA that high-dose influenza (commonly known as flu) vaccines are…
US DoD awarded $25 million contract to Hollingsworth & Vose to increase production capacity of filtration media
On Dec. 3, 2020, the U.S. Department of Defense in coordination with the Department of HHS, awarded a…
Biotechnology | Diagnostics | Disease | Infectious Disease | Medicine | Non-Profit Research | Therapeutics
University of Oregon opened the Phil and Penny Knight Campus for Accelerating Scientific Impact
On Dec. 2, 2020, the University of Oregon opened the Phil and Penny Knight Campus for Accelerating Scientific…
Biotechnology | COVID-19 | Therapeutics | WHO
Mateon announced development update for ARTIVEDA/ARTISHIELD against COVID-19
On Nov. 30, 2020, Mateon Therapeutics announced that the India arm of ARTI-19 global study was on track…
Innovation Pharma’s COVID-19 clinical trial supported development of Brilacidin as ‘Pan-Coronavirus’ therapeutic
On Nov. 30, 2020, Innovation Pharmaceuticals announced additional independent preliminary laboratory research suggests Brilacidin, the Company’s flagship defensin…
RedHill Biopharma expanded U.S.-based manufacturing capacity of opaganib for COVID-19
On Nov. 25, 2020, RedHill Biopharma announced partnerships with two leading, U.S.-based manufacturers for large-scale manufacturing of opaganib….
BioNTech and InstaDeep announce AI Innovation Lab to develop novel immunotherapies
On Nov. 25, 2020, BioNTech and InstaDeep announced a multi-year strategic collaboration aimed at applying the latest advances…
Biotechnology | COVID-19 | Disease | Therapeutics | Vaccine
NeuroRx and Relief announced successful results from expanded use of RLF-100 in patients with COVID-19
On Nov. 24, 2020, RELIEF THERAPEUTICS announced that more than 175 patients with Critical COVID-19 and Respiratory Failure…